Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 567

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 567
---
 | ​ | ​    | ​ | 3,382 | ​ | ​ | ​ | ​        | ​ | 3%   | ​ | ​ | ​ | ​                              | ​ | 10,443 | ​ | ​ | ​ | ​    | ​ | 10,746 | ​ | ​ | ​ | ​        | ​ | -3%  | ​ | ​ |
| Total G&A expense                              | ​ | ​ | ​                               | $ | 6,475 | ​ | ​ | ​ | ​    | $ | 6,755 | ​ | ​ | ​ | ​        | ​ | -4%  | ​ | ​ | ​ | ​                              | $ | 19,699 | ​ | ​ | ​ | ​    | $ | 21,191 | ​ | ​ | ​ | ​        | ​ | -7%  | ​ | ​ |

G&A expense was essentially flat between the three months ended September 30, 2024 and 2023. For the three months ended September 30, 2024 compared to the three months ended September 30, 2023, the decrease in stock compensation expense is primarily related to the reductions in workforce in January 2024 and June 2024, as well as additional workforce reductions during the three months ended September 2024. The increase in other G&A operating expenses for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was primarily due to Patheon minimum manufacturing orders of $0.6 million in 2024, partially offset by decreases in payroll and related costs, travel costs and other related conference costs. For the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023, the decrease in professional fees and public/investor relations was primarily due to decreases in legal costs. The increase in stock compensation expense is primarily related to performance-based restricted stock units that were achieved in March 2024, partially offset by the reductions in workforce in January 2024 and June 2024, as well as additional workforce reductions during the three months ended September 30, 2024. The decrease in other G&A operating expenses for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was primarily related to decreases in payroll and related costs, travel costs and other related conference costs, partially offset by Cara’s